Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
2023 · New England Journal of Medicine · 142 citations
https://doi.org/10.1056/nejmoa2212851
M
Marco Maruzzo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
306
Papers
3.4K
Citations
29
h-index
88
i10-index
Marco Maruzzo is an academic researcher from Istituto Oncologico Veneto. The author has contributed to research in topics: Renal cell carcinoma treatment & Cancer Immunotherapy and Biomarkers & Bladder and Urothelial Cancer Treatments. The author has an h-index of 29, co-authored 261 publications.
ORCID: 0000-0002-6256-9249Papers by this author
worksPazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience
2015 · Clinical Sarcoma Research · 84 citations
https://doi.org/10.1186/s13569-015-0022-2
Glycosaminoglycan Profiling in Patients’ Plasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma
2016 · Cell Reports · 57 citations
https://doi.org/10.1016/j.celrep.2016.04.056
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
2021 · ESMO Open · 54 citations
https://doi.org/10.1016/j.esmoop.2021.100118
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
2025 · New England Journal of Medicine · 32 citations
https://doi.org/10.1056/nejmoa2511885
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
2022 · ESMO Open · 31 citations
https://doi.org/10.1016/j.esmoop.2022.100634
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat